

19. Coles AJ, Compston DAC, Selmaj KW, et al. Alemtuzumab vs. Interferon beta-1a in early multiple sclerosis. *N Engl J Med* 2008; 359: 1786–1801.
20. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. *Lancet* 2012; 380: 1819–1828.
21. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. *Lancet* 2012; 380: 1829–1839.
22. Coles AJ, Cohen JA, Fox EJ, et al. CARE-MS II and CAMMS03409 Investigators. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. *Neurology* 2017; 89: 1117–1126.
23. Willis MD, Harding KE, Pickersgill TP, et al. Alemtuzumab for Multiple Sclerosis. *Mult Scler* 2016; 22: 1215–1223.
24. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. *N Engl J Med* 2010; 362: 402–415.
25. Buonomo AR, Zappulo E, Viceconte G, et al. Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis. *Expert Opin Drug Saf* 2018; 17: 709–717.
26. Costelloe L, Jones J, Coles A. Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis. *Expert Rev Neurother* 2012; 12: 335–341.
27. Coles AJ, Cohen JA, Fox EJ, et al. CARE-MS II and CAMMS03409 Investigators. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. *Neurology* 2017; 89: 1117–1126.
28. TOPAZ: 1. Coles AJ, et al. ACTRIMS-ECTRIMS 2017, Poster P1188; 2. Singer BV, et al. ACTRIMS-ECTRIMS 2017, Poster P736; 3. Traboulsee A, et al. AAN 2017, P2. 104; 4. Clinicaltrials.gov. <https://clinicaltrials.gov/ct2/show/NCT02255656>. Accessed September 7, 2017.